Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALL2820: Ponatinib + Blinatumomab versus Chemotherapy + Imatinib in Newly Diagnosed Adult Ph+ ALL
2023-508968-30-00Phase 3Authorised
- Sponsor
- GIMEMA
- Start
- Sep 2021
- Modality
- Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in acute lymphoblastic leukemia (ALL) comparing Sequential ponatinib + blinatumomab with Chemotherapy + imatinib (2 arms). Primary endpoint: Event-free survival. Planned start Sep 2021; status: authorised.
02
Drugs
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2023-508968-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508968-30-00.